Traders Purchase Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw some unusual options trading activity on Tuesday. Stock investors bought 41,153 call options on the stock. This represents an increase of 54% compared to the average daily volume of 26,799 call options.

Institutional Trading of SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in SELLAS Life Sciences Group by 168.2% in the 2nd quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock valued at $4,819,000 after buying an additional 1,379,988 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in SELLAS Life Sciences Group in the 2nd quarter valued at approximately $136,000. Rhumbline Advisers acquired a new position in SELLAS Life Sciences Group in the 2nd quarter valued at approximately $297,000. XTX Topco Ltd bought a new position in shares of SELLAS Life Sciences Group during the second quarter valued at $168,000. Finally, New York State Common Retirement Fund bought a new position in shares of SELLAS Life Sciences Group during the second quarter valued at $108,000. 17.38% of the stock is currently owned by institutional investors.

SELLAS Life Sciences Group Price Performance

SLS stock traded up $0.54 during trading on Tuesday, reaching $9.07. 7,204,963 shares of the company were exchanged, compared to its average volume of 8,047,852. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -39.43 and a beta of 2.50. The company has a 50-day moving average of $6.70 and a two-hundred day moving average of $4.94. SELLAS Life Sciences Group has a twelve month low of $1.39 and a twelve month high of $9.51.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. Maxim Group upped their target price on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.